Deep dive · NasdaqGS: DYN
Dyne Therapeutics, Inc. stock analysis
Everything behind the call on Dyne Therapeutics, Inc. 6 sections, ordered the way risk stacks up: survival first, quality and price in the middle, context last. The Beacon gives you the read. This is where you check the work.
The five reads
Why the reads disagreeread this before the sections
0 factors lean up and 4 lean down and one side is clearly ahead. The net lands at -7 over 30d, a moderate reading on a dispersion of 0.00, which makes this a question of size rather than of direction.
Leans down · and why
analyst moves, quality / value, earnings vote down. 5 of 5 families lean the other way.
What it changes
Size, not direction. dealers are long gamma, so their hedging absorbs moves rather than amplifying them; separately, the tail model puts a very bad day at −16.0%; and the binding position cap is 1.6% — the tail cap is the one that binds.
Global tapeOverseas lean0.00%
ZurichDYN0.00%⏱
Where else this company trades. A closed venue shows its last close, marked ⏱ — not a live price. Overseas lean is the average move across the 1 overseas venue listed above, excluding the home listing — a read on overnight sentiment rather than a signal.
The bottom linestart hereAs of 2026-09-25
Wall Street rating
Buy
+131% to the average target
94% buy · 6% hold · 0% sell
median target $37
median target $37
Chart pattern
Below both averages
The 50-day sits above the 200-day
50-day $23.29 · -31.2%
200-day $19.70 · -18.6%
200-day $19.70 · -18.6%
Earnings
In 40 days
5 Nov 2026 · options imply ±8.4%
beat 3–4 of the last 8
cohort P(beat) 53% · n=38,466
cohort P(beat) 53% · n=38,466
Valuation
-4.8× forward
Against consensus earnings
FCF yield -14.16%
Dividend
0.00%
A rounding error against cash — this is a capital-gains position
Risk flags
1 critical
5 checks run, 3 clear
beta 2.07 · vol 65% ann.
worst drawdown -40%
worst drawdown -40%
New to this? Every metric carries a plain-English read beside it, and an ⓘ next to a label opens the definition. Anything unfamiliar is also defined at the foot of the page under Glossary.
In one paragraphwhat the company actually does172 chars
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
NasdaqGS · USDBiotechnology
$16.03-0.48 · -2.91%CLOSED · vol 1.61M
52-week range↑ 34% off low · ↓ 41.3% off high
$11.92now $16.03$27.31
Quote Sep 25, 2026 · 4:00 PM ET
Tape 2026-09-25
Factors 2026-09-25
Tape 2026-09-25
Factors 2026-09-25
01Ratios · Jun 23, 2026SOLVENT · 1 FLAGGED
Survival & solvency
Altman-Z of 7.1 against a 3.0 safe threshold, and 3 of 5 forensic checks clear.
↳ Plain EnglishBefore anything else: can this company pay its bills? These blocks check the balance sheet, whether your slice of ownership is being diluted, and whether the accounting looks honest.
Bankruptcy risk (Altman-Z)
7.08SAFE ZONE
Distress<1.8
Grey1.8–3.0
Safe>3.0
Profitability, leverage and liquidity combined into one number. Above 3.0 is the safe band.
Balance sheetJun 23, 2026
Distance to default (Merton)COMFORTABLE
4.2σ
How many standard deviations of asset value sit between the company and its debt. Above 4σ is comfortable.
1-year default probabilityEDF-CALIBRATED
0.49%
Calibrated against how often companies at this distance actually defaulted, rather than assuming a normal distribution.
Piotroski F-scoreCRITICAL
F 3/8
Piotroski F-score 3 of 8. Nine pass/fail tests covering profitability, leverage and operating efficiency; seven or more is strong.
Solvency and liquidity ratios
Current ratioshort-term assets against short-term bills22.25×healthy >2
Debt / equityborrowings against shareholder capital0.17
Leverage · long-term debt / equitythe borrowings that outlive a bad quarter0.13
Net cashcash on hand in excess of every borrowing$724.17M
Your ownership stake
Share-count growth vs peersHIGH DILUTION
96th pctile
Where this name's share-count growth ranks among peers. Lower is less dilutive.
Accounting forensicsSEC filings
Red-flag x-rayGRADE B
75 / 100
1 critical · 0 watch · 3 clear of 4 scored tests
Red-flag x-ray · every check, passes included
CheckStatusValueWhat it looks for
Bankruptcy distressCLEARZ 8.28Altman-Z in the Safe · fundamentals
Earnings manipulationNAn/aBeneish-M not available · fundamentals
LeverageCLEARLTD/E 0.15long-term debt 0.15× equity · fundamentals
Profitability qualityCRITICALF 3/8Piotroski F-score 3 of 8 · fundamentals
Filing forensicsCLEAR0 flagsno filing red flags on the latest 10-K · forensic
5 checks, 3 clear and 1 critical. The passes are shown because a score built from five checks means something different from one built from three.
02Refreshed · Sep 26, 2026POOR · 22/100
Business quality
-46% return on equity, and capital earning -201% against a 13% cost.
↳ Plain EnglishMargins tell you how much of each sales dollar the company keeps. Return on capital tells you whether reinvesting that money creates value. Both are read against what the filings support, not against a target.
Quality score
22 / 100POOR
Profitability, growth and balance strength scored separately, then blended.
ProfitabilityRefreshed · Sep 26, 2026
Return on equityPER $1 OF EQUITY
-45.9%
Annual return on each dollar of shareholder equity.
ROIC − WACC spreadDESTROYS VALUE
-214.2pp
Earns -201% on invested capital that costs about 13%. A positive spread means every retained dollar compounds rather than leaks.
Incremental ROIC (3y)ON NEW CAPITAL
-216.5%
The return on capital put to work over the last three years — a sharper read than the trailing average, because it prices the newest decisions.
Asset growth vs peersWATCH
86th pctile
The balance sheet grew +72% on the year. Fast asset growth is usually a ramp; occasionally it is the start of an inventory problem.
Revenue (TTM)TRAILING
$0
Trailing twelve-month revenue from the latest filings.
Growth & relative strength
Trailing return by period
1 month-38.6%
3 months-24.6%
6 months-6.5%
Year to date-13.4%
1 year+27.4%
12-1 momentumEX LAST MONTH
+100.2%
Return over the last year excluding the most recent month — the standard momentum factor, which drops the short-term reversal.
Relative-strength rankBOTTOM 19%
19 / 100
Where this name's 3-month return against the S&P 500 ranks across the market — a quarter's standing, not the year's.
Around earningsJul 29, 2026
P(beat next quarter)COHORT BASE RATE
53%
survivor-tilted universe (currently-listed names; large-cap-skewed coverage)
Beat rate · this nameBEAT 3–4 OF THE LAST 8
4 of 8
Its own record against consensus. 8 prints is a small sample, which is why the cohort rate above carries the probability.
Fell after a beatP(FELL | BEAT)
20%
A beat is not a plan: this share of them still closed lower on the day.
Rose after a missP(ROSE | MISS)
62%
The mirror of the line above, over its own denominator.
Typical earnings moveMEDIAN ABSOLUTE
±3.2%
Unsigned magnitudes from its own prints. Direction is not part of this read.
Reaction: beat vs missData unavailableThe beat-versus-miss reaction gap is not computed for this name — undetermined — needs ≥12 measured beats.
Dividends & income
Data unavailableThis company does not pay a dividend. There is no yield, payout ratio or ex-dividend date to show, and the return case rests entirely on capital gains.
Signal
Not an income position.
No dividend is declared, so nothing here contributes to total return except the price. That is a fact about the security, not a criticism of it.
Inventory ledger
Data unavailableNo inventory detail is tagged in this company's filings. The ledger needs the XBRL inventory components, which a business without physical goods does not report.
Segments & geography
Data unavailableRevenue by segment and region is not on file for this name, so product and geographic concentration are not shown.
Pattern reliability · platform-wide cohortSnapshot · Sep 26, 2026
Downtrend · leans bearish
HorizonHigherMedianObservations
10d47%0.0%1,264,444
21d48%0.0%596,577
63d47%-0.6%187,417
slope -0.48 over 40 bars
Double top · leans bearish
HorizonHigherMedianObservations
10d50%0.0%1,216,877
21d51%+0.1%572,733
63d52%+0.3%181,607
two peaks ≈ equal — reversal if neckline breaks
Head and shoulders · leans bearish
HorizonHigherMedianObservations
10d49%0.0%499,633
21d51%+0.1%235,260
63d51%+0.3%74,900
head above two ≈-equal shoulders — bearish reversal
Falling wedge · leans bullish
HorizonHigherMedianObservations
10d50%0.0%430,231
21d50%0.0%203,310
63d50%+0.1%64,486
falling & converging — bullish
Rsi oversold · leans bullish
HorizonHigherMedianObservations
10d46%0.0%225,518
21d48%0.0%106,358
63d50%0.0%33,595
RSI 23 ≤ 30
03-4.8× FORWARD
Price & timing
Price $16.03, -4.8× forward earnings, RSI 22, and dealers long gamma.
↳ Plain EnglishA multiple is what the market charges for a dollar of this company's earnings, cash or revenue; the trend and the options tape say what the price is doing around it. Together they are the timing picture, not the quality one.
Trend
Below every average0 OF 3 AVERAGES
50-day $23.29 · 200-day $19.70. Price above both is the structural definition of an uptrend.
The setup right now
Price · 504 sessions2024-09-23 → 2026-09-25
price50-day200-daylevel
How to read this
Down 2.91% on the session.
Follow the solid line: each point is a session close. Compare it to the 50-day average — while price stays above it the short-term trend is up, and a drop below is the first structural warning.
The dashed levels are the strikes the options chain is most committed to. They are the same numbers the gamma block states; nothing here is drawn that no section derives.
Momentum (RSI-14)OVERSOLD
22
030 oversold70 hot100
Where momentum sits on a 0–100 scale. Above 70 is overbought, below 30 oversold; the middle says the move has room either way.
Typical day (ATR-14)±8.7%
$1.39
The average true range — how far this stock moves on an ordinary day. It sets the scale a stop has to clear.
MACDBELOW SIGNAL
-0.26
The short-term trend against its own signal line. The sign is the read; the size is not a target.
Bollinger position22% OF RANGE
Mid band
Where price sits inside its own volatility band. The edges are where a move is stretched, not where it reverses.
20-day VWAPPRICE BELOW
$19.31
The volume-weighted average of the last month. Price above it means recent buyers are, on average, in profit.
Chandelier exitBROKEN
$22.32
A volatility-based trailing stop, set a few average ranges below the recent high.
5 Nov 2026 · in 40 daysNext earningsThe next scheduled catalyst. The forward guide usually moves the tape more than the printed number. Date as the vendor last stated it on 9 Aug; companies confirm about three weeks ahead, so it can still move.
2026-09-29 · in 3 daysJob Openings (JOLTS)A scheduled macro release. It moves this stock independently of anything the company does.
Setup & oddsNightly
Direction oddsnext 12m
50 / 50cohort n=13,098
Effectively a coin flip. A split this close is not an edge you can size on, whichever side is nominally ahead. These are the cohort's odds — comparable names over the window — not this stock's own history.
Pullback riskoverstretch read
In line1.20× segment rate · n=12,184
Historically, mid names in this tape state saw a ≥10% pullback within 63 trading days in 95% of cases (n=12,184).
Overstretchvs the 20-day mean
-1.1σ
How many standard deviations price sits from its 20-day mean. Beyond 2σ is genuinely stretched; inside it is ordinary.
Bottom zoneif it breaks down
$15 – $162 supports
Where prior demand appeared: Pivot low at $15.87, S1 at $15.78.
Slide scorefalling-knife check
50 / 100Neutral
A composite of consecutive down days, gap risk and volume expansion. Low means any decline is orderly.
Signal
The odds are a coin flip.
Historically, names tripping 1 validated red flag finished lower 12 months later in 50% of cases (n=13,098) — a survivor-biased floor, not a forecast.
Valuation
Net cash per shareCASH BACKING
$4.39
Cash less every borrowing, per share. It is the part of the price that is not a claim on future profits.
Multiples
Forward P/EAnalysts expect a loss over the next twelve months, so there are no earnings for the price to be a multiple of.Not meaningful
Trailing P/EThe company lost money over the trailing year, so there are no earnings for the price to be a multiple of.Not meaningful
Price / bookprice against the accounting value of the assets3.1×
FCF yieldfree cash flow per dollar of market value-14.16%
1 of the 2 priced multiples above sits in the richer half of its band. 2 are marked not meaningful because the figure they divide into is negative — shown as absent rather than as a low, cheap-looking number. Each priced multiple is read against this stock's own history where a five-year range is on file, so the question is whether today is dear for this name rather than for the market. The multiples are computed separately from the quote above and are not re-priced as it moves, so they can lag it.
Price horizon & timingSep 25, 2026
Entryzone of pivot low + S1
$15.95In zone
Where the composer's entry sits, on its own stated basis.
TargetBb upper + 52-week high
$27.31$27–$28
A zone, not a price. It is where the composer expects supply, not a forecast.
Stop2× ATR below entry
$13.39risk $2.56/sh
The level that says the setup is wrong, on the basis named beside it.
Risk / rewardtarget vs stop
4.43:1
Reward against risk on the composer's own levels.
Measure from a price$
To the 50-day
+45.3%
short-term trend line · $23.29
To the 200-day
+22.9%
primary trend line · $19.70
To the put wall
+18.5%
heaviest put open interest · $19.00
To the call wall
+24.8%
heaviest call open interest · $20.00
To the composer's target
+70.4%
Bb upper + 52-week high · set Sep 25, 2026 · $27.31
To the composer's stop
-16.5%
2× ATR below entry · set Sep 25, 2026 · $13.39
To the 52-week high
+70.3%
highest print of the past year · $27.31
To the 52-week low
-25.6%
lowest print of the past year · $11.92
Options-implied week ±8.4%
$14.68 – $17.38
what the chain prices for the week
A typical day (ATR)
$14.64 – $17.42
±$1.39 average true range
Type any price to re-measure every distance from it. Each row is a level this page already states somewhere else, so nothing here is a new number — and none of it is a recommendation to trade at that price.
Signal
The levels line up.
Entry $15.95 · stop $13.39 · target $27.31, a 4.43:1 ratio. The composer flagged: far target.
Gamma mapChain · Sep 26, 2026
Signal
Long gamma — moves get absorbed.
Dealers hedge against the move, which damps volatility around the current strikes. It makes the tape quieter without saying anything about which way it goes.
Options tapeLast snapshot before the 2026-09-18 expiry · Chain · Sep 26, 2026
Max pain+2.6%
$18.00
The strike where most open options would have expired worthless on the last snapshot. That expiry has passed; the next chain read replaces it.
Put / call ratio (OI)CALL-HEAVY
0.16
86% calls
14% puts
Open interest in puts against calls. Heavy call interest often caps how far price can run before expiry.
Put / call ratio (volume)TODAY'S FLOW
0.35
Today's traded flow rather than the standing position. It moves faster and means less.
Expected move (1-week)≈ $1.48
±8.4%
What the chain prices for the week. A range the market is charging for, not a forecast.
Largest open interest · front expiry
StrikeTypeOpen interest
$20.00CALL1,118
$29.00CALL775
$26.00CALL508
$25.00CALL237
$19.00PUT204
$20.00PUT198
Large call interest above the price acts as a magnet and a ceiling; large put interest below is a floor of hedges. The biggest strike is the level the market is most committed to defending into the next expiry.
Open interest by strikeexpires 2026-09-18 (expired)CallsPutsMax pain $18.00
69
$30.00
1775
$29.00
02
$28.00
070
$27.00
0508
$26.00
0237
$25.00
1331
$24.00
23
$23.00
031
$22.00
049
$21.00
01k
$20.00
19852
$19.00
20412
$18.00
464
$17.00
100
$16.00
3210
$15.00
40
The shaded row is the strike nearest the price. Heavy call interest above acts as a ceiling; heavy put interest below is a floor of hedges.
↑ 52-week high$27.31+55.6%The highest print of the past year.Old highs draw profit-taking on the first attempt.
↑ Call wall$20.00+14.0%Heaviest call open interest on the front expiry.Acts as a ceiling into expiry; a close above usually needs a catalyst.
◇ Max pain$18.00+2.6%Where most open options expire worthless.Price often drifts toward it into the close of the expiry week.
↓ 50-day average$23.29+32.7%The line the short-term trend is measured against.A close beneath it is the first structural warning.
↓ Put wall$19.00+8.3%Heaviest put open interest — a floor of hedges.Dealer buying tends to build as price approaches.
0413F quarterly · Form 4 dailyNET SIGNAL -7
Ownership & flow
Institutions hold 104%, short interest is 14.19% of float, and 12 analysts average $37.
↳ Plain EnglishWho is buying and selling, and what they had to disclose. Institutions file 13F 45 days after quarter end, executives file Form 4 within two days, and Congress discloses under the STOCK Act with a 30–45 day legal lag. Every one of those is a look backwards.
Net signal
-7MODERATE · 30d
0 bull / 4 bear factors. The points sum to the net beside the label; nothing here is weighted after the fact.
The QTick signalNightly
Analyst moves90D · TIMING
-3
1 analyst downgrade in 90d
Earnings4 QUARTERS · TIMING
-1
latest EPS missed by 44%
Insider flow120D · TIMING
-1
net insider selling ($113,773,398 across 50 sells) in 120d
Quality / valueTTM · CONTEXT
-2
weak Piotroski F-score (3/8)
Signal
0 bull / 4 bear factors
Independent factors scored and netted to -7 over 30d, a moderate reading. 4 of 9 factors carried a direction; the others scored zero and do not vote. The signal describes where the data leans, not what to do about it.
Cross-category readSep 26, 2026
Signal
5 of 5 families lean down.
Descriptive only — a decorrelated read of where the evidence agrees and conflicts, not a forecast and not advice. Patterns are condition lists, not outcome predictions, and are not yet validated to the proof bar. Dispersion of 0.00 means the disagreement is real but not a split decision.
Wall Street12 covering firms
Consensus rating12 ANALYSTS
Buy
94% buy · 6% hold · 0% sell, as a share of the 12 covering firms.
Median price target+131%
$37
$10now $16$50
A $10–$50 spread across the panel. A twelve-month view, and a wide spread means real disagreement rather than a consensus.
Forward EPS estimateCONSENSUS
$-3.33
What the panel expects the company to earn per share.
Recent analyst moves · last 90 days
FirmTargetDirectionRank
Morgan Stanley$36↓51/100
JP Morgan$10↓53/100
RBC Capital$30↓53/100
Baird$26↓54/100
Morgan Stanley$45↓51/100
RBC Capital$35↑53/100
Cantor Fitzgerald—↑48/100
Upgrades, downgrades and target changes from covering firms. A cluster of moves in one direction matters more than any single target; the rank is the firm's own credibility score, or a dash below the scoring floor.
Who owns it13F quarterly · Form 4 daily
Institutional ownershipINSTITUTIONALLY HELD
103.6%
The share held by 13F filers. It describes last quarter's positioning, not today's — filings land up to 45 days after quarter end.
Insider ownershipOFFICERS & DIRECTORS
0.2%
The share held by the people running the company.
Short interest (float)CROWDED
14.19%
Rising — shares short changed +9.0% over 30 days. A crowded short is fuel in both directions.
Free float100% OF SHARES
164.74M
Shares actually available to trade, excluding insider and restricted holdings.
Dollar volume (ADV)78th PCTILE
$42.16M/day
Average dollars traded per day, and where that ranks cross-sectionally. Thin liquidity is a cost you pay on the way out, not just on the way in.
Borrow feeData unavailableWe do not license securities-lending data, so the annualized cost of borrowing shares to short is not something we can show. Short interest and days-to-cover above are the closest read we can source.
Insider filings · Form 4
InsiderTradeAmountPlanTraded
Friedl-Naderer Johanna · Chief Commercial OfficerSell$21,915—04 Sep
Cox John · Director, CEO & PresidentSell$106,823—08 Sep
Kerr Douglas · Chief Medical OfficerSell$24,355—08 Sep
Kerr Douglas · Chief Medical OfficerSell$91,191—04 Sep
Friedl-Naderer Johanna · Chief Commercial OfficerSell$3,493—08 Sep
Rhodes Jason P · DirectorSell$2.5M—13 Aug
Executives must file within two business days. Sales on pre-set 10b5-1 plans are scheduled months ahead and carry little signal; tax withholding, exercises and awards are compensation mechanics, not trades; the open-market lines are the ones to read.
The story · news & sentimentRolling window
Why it moved todayNEWS
-2.91%
DYN fell −2.91% since the last close, amid recent coverage: “Dyne Therapeutics Tumbles As RNA Therapy Hopes Dim - TipRanks” (TipRanks).
News tone · 7-day—
60 / 100
Headline polarity over the window, scored from news articles. Above 60 leans positive, below 40 negative. Colour, not a signal.
Newswire · 47 stories
WhenHeadlineSourceTone
FriDyne Therapeutics Tumbles As RNA Therapy Hopes Dim - TipRanksTipRanksnot scored
ThuDyne Therapeutics Tumbles As Hot-Streak Rally Cools - TipRanksTipRanksnot scored
WedDYN Oct 2026 19.000 call (DYN261016C00019000) stock price, news, quote and history - Yahoo Finance UKYahoo Finance UKnot scored
TueIs Dyne Therapeutics (DYN) Undervalued Following New ACHIEVE Trial Data Presentations? - simplywall.stsimplywall.stnot scored
Sep 20Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.commarketscreener.comnot scored
Sep 17New Dyne hires receive stock tied to 278,100 shares - Stock TitanStock Titannot scored
Sep 17Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? - Yahoo Finance SingaporeYahoo Finance Singaporenot scored
Sep 17Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? - Yahoo FinanceYahoo Financenot scored
Coverage published around the move, newest first. Nothing here measures causation — only the why-it-moved card above is matched to the tape by timestamp.
Congress
Data unavailableNo congressional trades in this name have been disclosed under the STOCK Act. Lawmakers' disclosed trades cluster heavily in large caps, so an empty list is the usual state.
0511 graded callsHIGH VOLATILITY
Risk & track record
Beta 2.07, 65% annual volatility, a -40% worst drawdown, and 3 of 8 risk surfaces clear.
↳ Plain EnglishWhat owning it does to a portfolio, what the model votes against, and how often our own calls have been right. Every call is graded when it resolves, and the ones still open stay visible.
A very bad day (EVT)
−16.0%1-IN-200 DAY
Fitted to the tail of the return distribution rather than assuming a bell curve. Size the position so a day like this is survivable.
What it does to a portfolio5-year window
Max drawdownWORST FALL
-40.1%
The deepest peak-to-trough fall in the measured window. Only hold a position you can watch do this.
Beta (vs the market)AMPLIFIES
2.07
Moves about 2.1× the market over the past year.
Annualized volatilityELEVATED
65%
How far it swings over a year, from its own realized returns.
Tactical phaseNIGHTLY READ
Neutral
Selling pressure60
Buying pressure0
Overheat0
State: neutral — No dominant short-horizon pressure in the tape.
What votes againstNightly
HighAnalyst moves1 analyst downgrade in 90d90d · -3
MedQuality / valueweak Piotroski F-score (3/8)TTM · -2
LowEarningslatest EPS missed by 44%4 quarters · -1
LowInsider flownet insider selling ($113,773,398 across 50 sells) in 120d120d · -1
Signal
4 of 9 factors vote against.
Ranked by the size of each factor's own point contribution to the net signal — these are the model's stated reasons, not a written bear case. Each one is scored from the source named beside it.
Failure modes · by company type
Data unavailableFailure modes are routed per company type, and only the bank-run and crypto-treasury rulebooks are validated so far. This name routes as growth, so there is no cohort-specific checklist to run. A generic list would read as analysis without being any.
The risk case · why not to buy8 surfaces · nightly
Suggested position capmax defensible size
1.6%tail cap binds
max defensible size 1.6% - tail binds
Avoid score6-month distress
13.9%1.5× its cohort · most-traded mega-caps
Observational 6-month large-drawdown risk ranking — not a forecast, not alpha. Historical distress rate for this most-traded mega-caps segment: 9.3%. This name reads 1.5× that base rate.
LowDistress screenThe distress model did not score this name in the latest run, so this surface is unmeasured rather than clear.Not scored
MedPosition size, not conviction, is the binding constrainthalf-Kelly 12.4% · tail cap 1.6% · category cap 54.6%. The tail cap binds, so 1.6% is the number (n=109,931). We show which one binds rather than the friendliest.Sizing
LowLottery-ticket behaviourIts best 21-day return sits at 4.4% against a 9.6% cohort 90th-percentile threshold — below the line where forward returns have historically turned negative.Behaviour
HighCash runwayAbout 6.5 quarters of cash at current burn ($753M cash against $462M a year of burn) - names in this bucket: 23.5% catastrophe rate within a year.Solvency
LowPost-earnings driftDrift odds at full strength (+3.21% / 63-day spread reference from measured post-earnings drift).Timing
LowDividend riskNot scored for this name.Not scored
HighRestatement history2 restatements in 2 years. The flagged-company base rate is 6.2× the unflagged one.Integrity
LowCrowded shortNot in a warn state: the crowded-short model only publishes when short interest and thin liquidity coincide, and neither condition is met here.Not scored
Signal
3 of 8 surfaces clear.
8 surfaces checked, 3 clear. The binding constraint is position size — the tail cap is the one that binds. Each row states which surface it is and what it measured; a surface that could not be scored says so rather than counting as clear.
Who should skip it
Skip it if any of these is you
You can't sit through -40%
That is this name's deepest measured fall, on 65% annualized volatility. A drawdown of that size is normal here, not exceptional.
You want income
A 0.00% yield is a rounding error against cash. This is a capital-gains position.
You're already heavy in this market
A 2.07 beta means you would be stacking the same bet rather than spreading it.
You'd be buying into earnings
A report lands in 40 days, and the chain prices ±8.4% for the week.
You'd size it like a core holding
The binding cap is 1.6% of a portfolio. Above that the tail stops being survivable.
Our track record11 resolved
Track recordBUILDING IN THE OPEN
20 logged
20 calls logged on this name, 11 resolved so far. Calls are logged the moment they are made, so the open ones are public before anyone knows how they turn out, and a hit-rate is not published until enough of them resolve.
Calls on DYNTHIS NAME
20
This name's own call count. Too few have resolved to publish a rate over them, so none is shown rather than a rate over 11.
0610-K disclosed linksBIOTECHNOLOGY
The wider context
5 mapped peers, 1 connection.
↳ Plain EnglishCompanies do not trade alone. This is the peer set, the supply chain that has to deliver, and the macro variables that move the stock regardless of company news.
Rate sensitivity
-8.9% per +1ppINSUFFICIENT
This is the SECTOR prior, not a measurement of this name — the regression did not clear its own bar. The verdict beside it (neutral) comes from the prior too, so the two agree by construction rather than by evidence.
Versus peersLatest session
Peer set · 5 names
SymbolRelationshipPriceSession
VRTXPeer$526.19+0.73%
REGNPeer$788.04-1.00%
ARGXPeer$959.49-0.28%
RVMDPeer$204.97+2.56%
ALNYPeer$255.96+2.55%
The mapped peer set and how each traded in the latest session. A peer moving with this name says the move is the sector's; one moving against it says the move is this company's.
Time machineHistory from 2023-06-01
Signal
2 of 4 backward windows are positive.
Look-back returns describe what happened, not what is likely. They are here to set the scale a future move would be measured on.
Macro driversRolling window
Next macro catalystIN 3 DAYS
Job Openings (JOLTS)
2026-09-29. A scheduled release that moves this stock independently of anything the company does.
Events · what moves this stockSep 26, 2026
Initial jobless claimsLittle effect either way
Healthcare demand does not depend on hiring.
Typical for the Healthcare sector
On the day -0.4% · A week later +0.1% · Two weeks later +1.0% · Rose on 76 of 171 report days
Across the last 171 Initial jobless claims reports since Jun 8, 2023, DYN moved -0.4% on average on the day and was 1.0% higher two weeks later. The S&P 500 moved 0.0% on those days.
Consumer sentiment (UMich) is due in 12 days.
Consumer sentiment (UMich)Little effect either wayLittle direct link.
Typical for the Healthcare sector
On the day +2.0% · A week later +2.4% · Two weeks later +1.6% · Rose on 23 of 39 report days
Across the last 39 Consumer sentiment (UMich) reports since Jun 26, 2023, DYN moved +2.0% on average on the day and was 1.6% higher two weeks later. The S&P 500 moved 0.0% on those days.
Core PCE (the Fed's gauge) is due in 3 days.
Core PCE (the Fed's gauge)Little effect either wayPeople need care regardless of prices; healthcare barely reacts to the print itself.
Typical for the Healthcare sector
On the day +0.5% · A week later +1.0% · Two weeks later -0.5% · Rose on 20 of 39 report days
Across the last 39 Core PCE (the Fed's gauge) reports since Jun 28, 2023, DYN moved +0.5% on average on the day and was 0.5% lower two weeks later. The S&P 500 moved +0.2% on those days.
FOMC decisionLittle effect either way
Healthcare demand does not depend on rates.
Typical for the Healthcare sector
On the day -2.3% · A week later -0.5% · Two weeks later -0.9% · Rose on 15 of 39 report days
Across the last 39 FOMC decision reports since Jul 1, 2023, DYN moved -2.3% on average on the day and was 0.9% lower two weeks later. The S&P 500 moved -0.1% on those days.
On the day +0.2% · A week later +2.8% · Two weeks later +2.9% · Rose on 19 of 39 report days
Across the last 39 Housing starts reports since Jun 20, 2023, DYN moved +0.2% on average on the day and was 2.9% higher two weeks later. The S&P 500 moved 0.0% on those days.
Industrial productionLittle effect either way
Healthcare does not track the business cycle.
Typical for the Healthcare sector
On the day -0.2% · A week later 0.0% · Two weeks later +3.0% · Rose on 16 of 39 report days
Across the last 39 Industrial production reports since Jun 15, 2023, DYN moved -0.2% on average on the day and was 3.0% higher two weeks later. The S&P 500 moved +0.1% on those days.
Job openings (JOLTS) is due in 2 days.
Job openings (JOLTS)Little effect either wayHealthcare demand does not depend on hiring.
Typical for the Healthcare sector
On the day +0.1% · A week later -1.0% · Two weeks later +1.0% · Rose on 17 of 39 report days
Across the last 39 Job openings (JOLTS) reports since Jul 5, 2023, DYN moved +0.1% on average on the day and was 1.0% higher two weeks later. The S&P 500 moved 0.0% on those days.
Jobs report (nonfarm payrolls) is due in 5 days.
Jobs report (nonfarm payrolls)Little effect either wayHealthcare demand does not depend on hiring.
Typical for the Healthcare sector
On the day -0.7% · A week later -1.3% · Two weeks later +1.1% · Rose on 15 of 39 report days
Across the last 39 Jobs report (nonfarm payrolls) reports since Jul 6, 2023, DYN moved -0.7% on average on the day and was 1.1% higher two weeks later. The S&P 500 moved -0.1% on those days.
Customer momentum
Data unavailableCustomer momentum needs listed customers that disclose a revenue dependence on this company, and none is on file. The connections below are a different map: competitors and partners, most of them curated rather than filed.
Connections1 link · 1 confirmed
Direct connections · 1 edge
CompanyRelationSessionProvenance
SRPT · Competitorcompetitor+1.52%Confirmed · manual
1 of 1 edge is named in a filing; the rest come from reporting we have not matched to one yet, and are labelled as such.
Suppliers, customers & competitors
Named competitors
SRPTCompetitorcompetitor
Glossary · every term on this page
Survival
Altman Z
Bankruptcy-risk score. Above 3.0 is the safe band.
Piotroski F
Nine pass/fail health tests; 7 or more is strong.
Beneish M
Accrual and growth pattern screen. Clear below −2.22, watch to −1.78, elevated above; a year of very fast revenue growth lifts it by construction.
Merton DTD
Standard deviations of asset value between the company and its debt.
EDF
Default frequency calibrated on what actually happened to similar names.
Price & tape
RSI-14
Momentum gauge 0–100. Above 70 is overbought, below 30 oversold.
ATR
Average true range — the size of a typical day.
VWAP
20-day volume-weighted average price — the average paid over the last month; the page shows no intraday VWAP.
Supertrend
A trend-following stop line. A close through it flips the read.
Chandelier
A trailing stop set a few average ranges below the recent high.
Options & flow
Gamma / GEX
Dealer hedging pressure. Negative gamma amplifies moves both ways.
Call / put wall
The strikes with the heaviest open interest; they act as ceiling and floor.
Max pain
The strike where most options expire worthless.
13F · Form 4
Institutional filings, 45 days after quarter end. Insider trades, within two days.
Scoring
Composite signal
Independent factors scored and netted into one number.
Hit-rate
Share of past calls that resolved in the direction stated.
Brier score
Calibration measure. Lower means stated probabilities track reality.
HHI
Concentration 0–10,000. Above 2,500 means one segment carries the company.
EVT
Fits the tail rather than assuming a bell curve, so bad days are not understated.